The Firm – Faruqi & Faruqi LLP

Story and History

Since its founding in 1995, Faruqi & Faruqi has served as lead or co-lead counsel in numerous high-profile cases which ultimately provided significant recoveries to investors, consumers and employees.

Values and Philosophy

Value is a core part of our firm’s professional philosophy. We strive everyday to provide quality legal representation to our clients. This value driven approach is what you should expect from the law firm you select to handle your case. We demand that every member of our team deliver this value day in and day out.

Mission and Services

Faruqi & Faruqi, LLP is here to help our clients by providing them with a high degree of excellence in legal counsel.

Court Praises

The standing and ability of both petitioning counsel [Faruqi & Faruqi, LLP was one of the co-lead counsel]… is among the highest in our bar."

Vice Chancellor Sam Glasscock, III

Chancery Court of Delaware

I feel that counsel for plaintiffs evidenced that they were and are skilled in the field of securities litigation."

Judge Justin L. Quackenbush

United States District Court, District of Nevada

Although all of the firms seeking appointment as Lead Counsel have impressive resumes, the Court is most impressed with Faruqi & Faruqi."

Judge Timothy S. Black

United States District Court, Southern District of Ohio

There is no doubt that the law firms involved in this matter represented in my opinion the cream of the crop of class action business law and mergers and acquisitions litigators..."

Ira B. Warshawsky

Supreme Court of the State of New York, County of Nassau, Hon.

Plaintiffs Co-Lead Counsel have conducted the litigation and achieved the Settlement with skill, perseverance and diligent advocacy.”

Judge Freda L. Wolfson

United States District Court, District of New Jersey

It is undisputed that counsel for the Plaintiffs are extremely competent and possess the necessary skills to represent Plaintiffs herein.”

Judge Michael D. Mason

Circuit Court for Montgomery County, Maryland

Faruqi & Faruqi has extensive experience in the area of securities litigation and class actions. The firm’s resume indicates that it has litigated more than ten prominent securities class actions since its founding in 1995.”

Kimba M. Wood

United States District Court,  Southern District of New York

Prior Case Disclaimer

The information contained in the Faruqi & Faruqi, LLP (“Faruqi & Faruqi” or the “firm”) Web site is provided for informational purposes only, and should not be construed as legal advice on any subject matter.

No recipients of content from this site, client or otherwise, should act or refrain from acting on the basis of any content included in the site without seeking the appropriate legal or professional advice on the particular facts and circumstances at issue from an attorney licensed in the recipient’s state. The content of this Web site contains general information and may not reflect current legal developments, verdicts or settlements. Faruqi & Faruqi expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this site.

If you are interested in viewing information about Faruqi & Faruqi’s past results, please read and acknowledge the information below. The information in this section contains information about the firm’s past results, and may contain testimonials and statements regarding the firm’s quality. This information has not been reviewed or approved by the Florida Bar.

You should know the following:

1. The facts and circumstances of your case may differ from the matters in which results and testimonials have been provided;
2. All results of cases handled by the firm are not provided;
3. And the results provided are not necessarily representative of results obtained by the firm or of the experience of all clients or others with the firm.

Commitment to Diversity

Faruqi & Faruqi, LLP is committed to equal employment opportunities. We are a firm founded by minorities and will not discriminate against employees or applicants for employment on any legally-recognized basis including, but not limited to: veteran status, uniform servicemember status, race, color, religion, sex, national origin, age, physical or mental disability, genetic information or any other protected class under the federal, state or local laws. Faruqi & Faruqi, LLP is also committed to providing equal employment opportunities to qualified individuals with disabilities. Faruqi & Faruqi, LLP is certified as a Women’s Business Enterprise (WBE) through the Women’s Business Enterprise National Council (WBENC), the nation’s largest third party certifier of businesses owned and operated by women in the US.

We strive to create the best possible climate for maximum development and goal achievement for all employees. Our practice is to treat each employee as an individual. We seek to develop a spirit of teamwork; individuals working together to attain a common goal. In order to maintain an atmosphere where these goals can be accomplished, we provide a comfortable and progressive workplace. Most importantly, we have a workplace where communication is open and problems can be discussed and resolved in a mutually respectful atmosphere.

Do you need legal assistance?

Do not hesitate to contact us with any enquiries.

(877) 247-4292 (212) 983-9330

Stay up-to-date

Latest Postings from Our Offices

Investigations

Cases

News

Blog

17 Oct 2025

Baxter International, Inc.

Did You Lose Money in Baxter International, Inc. (NYSE: BAX) Stock? Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International, Inc. (“Baxter” or the “Company”) for alleged violations of federal securities laws. The firm reminds investors that they have until December 15, 2025 to seek appointment as lead plaintiff in the class action filed against the Company. The complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter’s attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter’s statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading. If you purchased BAX securities between February 23, 2022 and July 30, 2025 , you may be eligible to recover your losses. Lead Plaintiff Deadline: December 15, 2025 📞 Call Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) 💻 Or submit your information below to learn about your rights.

James M. Wilson, Jr.

Robert W. Killorin

Lead Plaintiff Deadline

53 Days

Take Action

13 Oct 2025

Tvardi Therapeutics, Inc.

If you suffered significant losses in Tvardi stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD). STOCK DROP: On Monday, October 13, 2025, Tvardi Therapeutics, Inc. saw its shares plummet over 80% after disappointing preliminary data from the Phase 2 REVERT clinical trial of TTI-101 in idiopathic pulmonary fibrosis. The study was designed to assess safety, pharmacokinetics, and exploratory outcomes related to lung function. After reviewing the preliminary safety data and exploratory efficacy results, including changes in Forced Vital Capacity (FVC), the Company concluded that the study did not meet its goals. Preliminary data demonstrated patients’ baseline characteristics were similar across treatment arms, with the exception of percent predicted FVC, which was lower in the placebo-treated patients compared to the TTI-101-treated arms.

James M. Wilson, Jr.

Robert W. Killorin

Take Action

18 Mar 2025

Caribou Biosciences, Inc.

On March 25, 2025, Honorable Vince Chhabria of the Northern District of California appointed Faruqi & Faruqi, LLP, as sole lead counsel in Saylor v. Caribou Biosciences, Inc. et al, Docket No. 3:24-cv-09413 (N.D. Cal. Dec 24, 2024). The Caribou Biosciences, Inc. class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) they had overstated CB-010’s safety, efficacy, and durability relative to approved autologous CAR-T cell therapies in treating patients with r/r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (ii) Caribou was at significant risk of having insufficient cash, liquidity, and/or other capital to fund its current business operations, including preclinical research activities associated with the allogeneic CAR-NK platform; and (iii) all the foregoing was likely to have a significant negative impact on Caribou’s business and operations. For further inquiries regarding this matter, please contact James M. Wilson, Jr. at jwilson@faruqilaw.com or (212) 983-9330. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

James M. Wilson, Jr.

Robert W. Killorin

18 Mar 2025

Methode Electronics, Inc.

On February 3, 2025, Honorable Sara L. Ellis of the Northern District of Illinois appointed Faruqi & Faruqi, LLP, as sole lead counsel in Salem v. Methode Electronics, Inc. et al, Docket No. 1:24-cv-07696 (N.D. Ill. Aug 26, 2024). The Methode Electronics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Methode Electronics had lost highly skilled and experienced employees during the COVID-19 pandemic necessary to successfully complete Methode Electronics’ transition from its historic low mix, high volume production model to a high mix, low production model at its Monterrey facility; (ii) Methode Electronics’ attempts to replace its General Motors center console production with more diversified, specialized products for a wider array of vehicle manufacturers and OEMs, in particular in the electric vehicle (“EV”) space, had been plagued by production planning deficiencies, inventory shortages, vendor and supplier problems, and, ultimately, botched execution of Methode Electronics’ strategic plans; (iii) Methode Electronics’ manufacturing systems at its critical Monterrey facility suffered from a variety of logistical defects, such as improper system coding, shipping errors, erroneous delivery times, deficient quality control systems, and failures to timely and efficiently procure necessary raw materials; (iv) Methode Electronics had fallen substantially behind on the launch of new EV programs out of its Monterrey facility, preventing Methode Electronics from timely receiving revenue from new EV program awards; and (v) as a result, Methode Electronics was not on track to achieve the 2023 diluted earnings-per-share guidance or the 3-year 6% organic sales compound annual growth rate represented to investors and such estimates lacked a reasonable factual basis. For further inquiries regarding this matter, please contact James M. Wilson, Jr. at jwilson@faruqilaw.com or (212) 983-9330. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

James M. Wilson, Jr.

Robert W. Killorin

12 Sep 2025

Faruqi & Faruqi Beats Motion to Dismiss in Luminar Technologies Securities Litigation and Advances the Case to Discovery